Morgan Stanley
IPHA

Morgan Stanley’s Innate Pharma IPHA Stock Holding History

Morgan Stanley’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.7K Sell
43,524
-2,870
-6% -$4.69K ﹤0.01% 6386
2025
Q4 		$81.2K Sell
46,394
-7,170
-13% -$13.8K ﹤0.01% 6274
2025
Q3 		$103K Buy
53,564
+2,340
+5% +$4.71K ﹤0.01% 6137
2025
Q2 		$93K Buy
51,224
+7,700
+18% +$15.6K ﹤0.01% 6161
2025
Q1 		$77.5K Hold
43,524
– – ﹤0.01% 6122
2024
Q4 		$80.1K Hold
43,524
– – ﹤0.01% 6141
2024
Q3 		$99.7K Hold
43,524
– – ﹤0.01% 6013
2024
Q2 		$84.4K Sell
43,524
-600
-1% -$1.51K ﹤0.01% 6020
2024
Q1 		$127K Sell
44,124
-48,584
-52% -$127K ﹤0.01% 5894
2023
Q4 		$260K Buy
92,708
+47,754
+106% +$119K ﹤0.01% 5848
2023
Q3 		$114K Sell
44,954
-2,095
-4% -$6.14K ﹤0.01% 5828
2023
Q2 		$145K Sell
47,049
-1,673
-3% -$5.14K ﹤0.01% 5784
2023
Q1 		$139K Sell
48,722
-645
-1% -$2.07K ﹤0.01% 5874
2022
Q4 		$184K Sell
49,367
-7,485
-13% -$17.1K ﹤0.01% 5698
2022
Q3 		$114K Buy
56,852
+10,254
+22% +$27.7K ﹤0.01% 6010
2022
Q2 		$126K Buy
46,598
+1,644
+4% +$4.78K ﹤0.01% 6149
2022
Q1 		$151K Buy
44,954
+5,624
+14% +$20.8K ﹤0.01% 6071
2021
Q4 		$180K Buy
39,330
+21,601
+122% +$115K ﹤0.01% 6129
2021
Q3 		$109K Sell
17,729
-18,901
-52% -$81.4K ﹤0.01% 6315
2021
Q2 		$121K Sell
36,630
-19,480
-35% -$77.7K ﹤0.01% 6268
2021
Q1 		$242K Buy
56,110
+50,980
+994% +$228K ﹤0.01% 5547
2020
Q4 		$21K Buy
5,130
+3,559
+227% +$15.9K ﹤0.01% 6420
2020
Q3 		$6K Sell
1,571
-10,870
-87% -$61.7K ﹤0.01% 6409
2020
Q2 		$85K Buy
12,441
+9,141
+277% +$61.2K ﹤0.01% 5481
2020
Q1 		$22K Buy
+3,300
New +$22.2K ﹤0.01% 5774

Other funds holding IPHA

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's IPHA Position: Q1 2026 in Review

Morgan Stanley reduced its Innate Pharma (IPHA) stake by 6.2% in Q1 2026, selling an estimated $4.69K and leaving 43,524 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6386.

Morgan Stanley first reported a position in IPHA in Q1 2020 and has held it in 25 quarters since. The position peaked at $260K in Q4 2023. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

  • Morgan Stanley held 43,524 shares of Innate Pharma worth $55.7K as of Q1 2026.
  • Morgan Stanley sold 2,870 Innate Pharma shares in Q1 2026, an estimated $4.69K.
  • Innate Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6386 holding.
  • Morgan Stanley first reported a position in Innate Pharma in Q1 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Innate Pharma position peaked at $260K in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.